Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;63(2):e39-e42.
doi: 10.1093/rheumatology/kead395.

The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort

Alessandro Tomelleri  1   2 , Giovanni Benanti  1   2 , Adriana Cariddi  1 , Stefania Laura Calvisi  1 , Elena Baldissera  1 , Nicola Boffini  1 , Marco Matucci-Cerinic  1   3 , Lorenzo Dagna  1   2
Affiliations

The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort

Alessandro Tomelleri et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

References

    1. Nash P, Kerschbaumer A, Dörner T. et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021;80:71–87. - PMC - PubMed
    1. Ytterberg SR, Bhatt DL, Mikuls TR. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386:316–26. - PubMed
    1. Winthrop KL, Cohen SB.. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol 2022;18:301–4. - PMC - PubMed
    1. European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. www.ema.europa.eu/contact (6 April 2023, date last accessed).
    1. Philippoteaux C, Deprez V, Nottez A. et al. Characteristics of patients treated with JAK inhibitors in rheumatoid arthritis before versus after VTE risk warnings. J Clin Med 2022;12:207. - PMC - PubMed

Grants and funding